Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04182932
Other study ID # CJ_HFM_101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 2, 2019
Est. completion date December 2021

Study information

Verified date December 2019
Source CJ HealthCare Corporation
Contact Sun Young Wang
Phone +82-2-6477-0286
Email sy.wang@kolmar.co.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the safety and immunogenicity of CJ-40010 after administration in healthy subjects


Description:

Enterovirus 71(EV71) and coxsackievirus A16(CVA16) are major causes of Hand-foot-and-mouth disease (HFMD) occurring in pediatric population. Although EV71 vaccine has been licensed in China, vaccine for CVA16-associated HFMD is currently not available anywhere. The purpose of this phase I study is to evaluate the safety and immunogenicity of EV71/CVA16 bivalent vaccine in healthy adults.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2021
Est. primary completion date November 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 49 Years
Eligibility Inclusion Criteria:

- Healthy adult men and women aged =19 to <50 years at the time of screening tests

- Body mass index(BMI)* of =18.0 kg/m2 to =27.0 kg/m2, with body weight of =55.0 kg to =90.0 kg for men and =50.0 kg to =90.0 kg for women at the time of screening tests

*BMI (kg/m2) = Body weight (kg) / {height (m)}2

- Determined by the investigator to be eligible for study participation based on the results of screening tests (medical examination by interview, physical examination, vital signs, ECG, and clinical laboratory tests) conducted within 4 weeks of the 1st IP administration

- Intact deltoid muscle* that allows administration of the investigational product

*Those who have a wound, scar, tattoo, skin disorder or infection on the expected investigational product administration site (deltoid muscle) that can affect safety evaluation cannot enter the study

- Consent to use medically acceptable contraception* throughout the study

*Medically acceptable contraception: Use of an intrauterine device with a demonstrated pregnancy failure rate, concurrent use of a barrier method (male or female) and spermicide, surgical contraception of the subject or partner (vasectomy, salpingectomy/tubal ligation, hysterectomy, bilateral oophorectomy)

- Negative finding from a pregnancy test (urine hCG) at the time of the screening visit, after using medically acceptable contraception prior to 30 days of screening for women of childbearing potential*

*Women of childbearing potential: Women who have not passed 1 year after menopause or not surgically sterilized (hysterectomy, bilateral oophorectomy)

- Voluntary decision and provision of written consent on participation in this study

Exclusion Criteria:

- History of a hand-foot-mouth disease or history of a disease related with enterovirus(EV) infection such as herpangina, viral meningitis, encephalitis, acute hemorrhagic conjunctivitis or myocarditis within 3 months prior to the 1st IP administration

- Medical history of an anaphylactic or similar acute reaction to CJ-40010 or similar vaccine

- Febrile disease or infectious disease within 2 weeks prior to the 1st IP administration

- Whole blood donation within 2 months or apheresis within 1 month prior to the 1st IP administration

- Vaccination with other prevention vaccine within 2 months prior to the 1st IP administration

- Use of an immunomodulator or immunosuppressant* within 3 months prior to the 1st IP administration

- e.g., Azathioprine, Cyclosporin, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus

- High dose corticosteroids (continuous use for 14 days or more at =20 mg/day for Prednisolone. However, use of inhaled, intranasal or topical corticosteroids is allowed irrespective of the administered dose).

- History of a Guillain Barre syndrome

- Excessive caffeine intake (>5 units/day) or continuous alcohol consumption (>21 units/week, 1 unit = 10 g of pure alcohol) or incapable of abstention from alcohol during the study

- Participation in other clinical trial within 6 months prior to the 1st IP administration

- Pregnant or breastfeeding women

- Clinically significant hepatic, renal, neurological, respiratory, endocrine, hematology and oncology, cardiovascular, urological or psychiatric disease or such history

- Positive serological finding (type B hepatitis test, type C hepatitis test, human immunodeficiency virus(HIV) test)

- History of drug abuse or positive finding from a urine screening test for an abusive drug

- Use or of any prescription medication or oriental medicine within 2 weeks or any over-the-counter(OTC) medication, health functional food or vitamin within 1 week prior to the 1st IP administration (however, those who administered an allowed drug as specified in the other exclusion criterion can enter the study) or expected use of such products

- Administration of a blood product or blood-derived agent within 3 months prior to the 1st IP administration

- Determined by the investigator to be ineligible for study participation due to other reason including clinical laboratory findings

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CJ-40010 EV71 vaccine A dose
Inactivated vaccine against EV71, three doses, 28 days interval
CJ-40010 EV71 vaccine B dose
Inactivated vaccine against EV71, three doses, 28 days interval
CJ-40010 CVA16 vaccine C dose
Inactivated vaccine against CVA16, three doses, 28 days interval
CJ-40010 CVA16 vaccine D dose
Inactivated vaccine against CVA16, three doses, 28 days interval
CJ-40010 Bivalent vaccine E dose
Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
CJ-40010 Bivalent vaccine high dose
Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
Placebo
Placebo, three doses, 28 days interval

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital, Clinical Trial Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
CJ HealthCare Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency and severity of adverse events of CJ-40010 (Safety of CJ-40010) - Frequency and severity of adverse events up to 32 weeks post first dose Week 0 to Week 32
Secondary Immunogenicity of CJ-40010 : Anti-EV71 IgG titer Serum EV71-specific IgG titers Week 0 to Week 32
Secondary Immunogenicity of CJ-40010 : Anti-CVA16 IgG titer Serum CVA16-specific IgG titers Week 0 to Week 32
Secondary Immunogenicity of CJ-40010 : Geometric mean titer (GMT) of EV71 neutralizing antibody titers Geometric mean titers based on neutralizing antibody titers. Measurement of fold-increase over baseline of neutralizing titers against EV71 Week 0 to Week 32
Secondary Immunogenicity of CJ-40010 : GMT of CVA16 neutralizing antibody titers Geometric mean titers based on neutralizing antibody titers. Measurement of fold-increase over baseline of neutralizing titers against CVA16 Week 0 to Week 32
See also
  Status Clinical Trial Phase
Recruiting NCT06063057 - Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial Phase 1/Phase 2
Completed NCT04133584 - The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine Phase 4
Completed NCT03241030 - Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Phase 2
Completed NCT01255124 - Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children N/A
Completed NCT03873740 - Immunogenicity and Safety of Two Different Commercial EV71 Vaccines Phase 4
Completed NCT05637229 - A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia
Recruiting NCT06146088 - Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine Phase 4
Active, not recruiting NCT06209398 - Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine Phase 4
Recruiting NCT01145664 - A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease N/A
Recruiting NCT01175915 - A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Completed NCT01182532 - A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Completed NCT03281174 - Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine N/A
Completed NCT03582761 - Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71 Phase 4
Completed NCT03903926 - Efficacy Trial of a Commercial EV71 Vaccine Phase 4
Completed NCT02001233 - A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
Completed NCT03909074 - Clinical Trial of Enterovirus 71(EV71) Inactivated Vaccine in Children Aged 36-71 Months Phase 3
Completed NCT01769794 - Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study N/A
Recruiting NCT01182025 - A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Recruiting NCT06263439 - Surveillance of HFMD in Pediatric Outpatients
Not yet recruiting NCT05397587 - An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell) Phase 4